Nor-Ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases
Abstract
Norursodeoxycholic acid (norUDCA) is a side-chain-shortened derivative of ursodeoxycholic acid with relative resistance to amidation, which enables its cholehepatic shunting. Based on its specific pharmacologic properties, norUDCA is a promising drug for a range of cholestatic liver and bile duct disorders. Recently, norUDCA has been successfully tested clinically in patients with primary sclerosing cholangitis (PSC) as first application in patients. Moreover, hepatic enrichment of norUDCA facilitates direct therapeutic effects on both parenchymal and non-parenchymal liver cells, thereby counteracting cholestasis, steatosis, hepatic inflammation and fibrosis, inhibiting hepatocellular proliferation, and promoting autophagy. This may open its therapeutic use to other non-cholestatic and metabolic liver diseases. This review article is a summary of a lecture given at the XXIV International Bile Acid Meeting (Falk Symposium 203) on "Bile Acids in Health and Disease" held in Düsseldorf, on June 17-18, 2016 and summarizes the recent progress of norUDCA as novel therapeutic approach in cholestatic and metabolic liver disorders with a specific focus on PSC.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
norUDCA does not act via FXR or other NRs.
“Notably, norUDCA does not act via FXR or other NRs,213”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [213]
Since norUDCA reinforces the HCO3- umbrella, it may also be a therapeutic approach in other cholangiopathies with defective HCO3- secretion such as PBC.
“Since norUDCA reinforces the HCO3 – umbrella2 it may also be a therapeutic approach in other cholangiopathies with defective HCO3 – secretion such as PBC.213”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [213]
Cites
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., Luketic, V. A. C., Harrison, E. M., McCashland, T., Befeler, A. S., Harnois, D., Jorgensen, R., Petz, J., Keach, J., et al. (2009) · Hepatology · doi:10.1002/hep.23082 · Cited by 720 · see citing works
Th, M., van Nieuwkerk, C. M., Dingemans, K. P., Smit, J. J., Schinkel, A. H., Notenboom, R. G. E., Weerman, M. A. V. D. B., VERKRUISEN, R. P., Groen, A. K., & Elferink, R. P. J. O. (1994) · PubMed Central · Cited by 352 · see citing works
Hohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315 · see citing works
Fickert, P., Zollner, G., Fuchsbichler, A., Stumptner, C., Weiglein, A. H., Lammert, F., Marschall, H., Tsybrovskyy, O., Zatloukal, K., Denk, H., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35948 · Cited by 312 · see citing works
Fickert, P., Wagner, M., Marschall, H., Fuchsbichler, A., Zollner, G., Tsybrovskyy, O., Zatloukal, K., Liu, J., Waalkes, M. P., Cover, C., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.018 · Cited by 301 · see citing works
Yoon, Y. B., Hagey, L. R., Hofmann, A. F., Gurantz, D., Michelotti, E. L., & Steinbagh, J. H. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90859-0 · Cited by 248 · see citing works
Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse.
Elferink, R. P. J. O., Ottenhoff, R., van Wijland, M. J. A., Smit, J., Schinkel, A. H., & Groen, A. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117658 · Cited by 225 · see citing works
Moustafa, T., Fickert, P., Magnes, C., Guelly, C., Thueringer, A., Frank, S., Kratky, D., Sattler, W., Reicher, H., Sinner, F. M., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.051 · Cited by 163 · see citing works
Halilbasic, E., Fiorotto, R., Fickert, P., Marschall, H., Moustafa, T., Spirlı̀, C., Fuchsbichler, A., Gumhold, J., Silbert, D., Zatloukal, K., et al. (2009) · Hepatology · doi:10.1002/hep.22891 · Cited by 157 · see citing works
García‐Rodríguez, J. L., Barbier‐Torres, L., Fernández-Álvarez, S., Juan, V. G., Monte, M. J., Halilbasic, E., Herranz, D., Álvarez, L., Aspichueta, P., Marı́n, J. J. G., et al. (2013) · Hepatology · doi:10.1002/hep.26971 · Cited by 128 · see citing works
Fiorotto, R., Spirlı̀, C., Fabris, L., Cadamuro, M., Okolicsànyi, L., & Strazzabosco, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.071 · Cited by 115 · see citing works
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice
Fickert, P., Pollheimer, M. J., Silbert, D., Moustafa, T., Halilbasic, E., Krones, E., Durchschein, F., Thüringer, A., Zollner, G., Denk, H., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.026 · Cited by 100 · see citing works
Imam, M. H., Sinakos, E., Gossard, A. A., Kowdley, K. V., Luketic, V. A., Harrison, M. E., McCashland, T. M., Befeler, A. S., Harnois, D. M., Jorgensen, R. A., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04863.x · Cited by 88 · see citing works
Sombetzki, M., Fuchs, C. D., Fickert, P., Österreicher, C. H., Mueller, M., Claudel, T., Loebermann, M., Engelmann, R., Langner, C., Sahin, E., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.020 · Cited by 69 · see citing works
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
Trauner, M. A., Halilbasic, E., Claudel, T., Steinacher, D., Fuchs, C. D., Moustafa, T., Pollheimer, M. J., Krones, E., Kienbacher, C., Traussnigg, S., et al. (2015) · Digestive Diseases · doi:10.1159/000371904 · Cited by 49 · see citing works
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
Beraza, N., Ofner‐Ziegenfuß, L., Ehedego, H., Boekschoten, M. V., Bischoff, S. C., Müller, M. M., Trauner, M. A., & Trautwein, C. (2010) · Gut · doi:10.1136/gut.2010.223834 · Cited by 47 · see citing works
Tang, Y., Fickert, P., Trauner, M. A., Marcus, N. Y., Blomenkamp, K., & Teckman, J. H. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00143.2015 · Cited by 32 · see citing works
Buko, V., Lukivskaya, O., Naruta, E. E., Belonovskaya, E., & Tauschel, H. (2014) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2014.02.001 · Cited by 23 · see citing works
Trauner, M. A., Fickert, P., Hirschfield, G. M., Reiter, F. P., Altorjay, I. F., Marschall, H., Färkkilä, M. A., Schramm, C., Spengler, U., Chapman, R. W., et al. (2016) · Journal of Hepatology · doi:10.1016/s0168-8278(16)00171-9 · Cited by 10 · see citing works
Fickert, P., Moustafa, T., Fuchsbichler, A., Claudel, T., Halilbasic, E., Zatloukal, K., Denk, H., & Trauner, M. A. (2008) · Journal of Hepatology · doi:10.1016/s0168-8278(08)60100-2 · Cited by 7 · see citing works
Trauner, M. A., Fickert, P., Hirschfield, G. M., Denk, G., Altorjay, I., Marschall, H., Färkkilä, M. A., Schramm, C., Spengler, U., Chapman, R. W., et al. (2016) · Hepatology · Cited by 4 · see citing works
Moustafa, T., Halilbasic, E., Fickert, P., Fuchsbichler, A., Gumhold, J., Silbert, D., Denk, H., & Trauner, M. A. (2008) · Journal of Hepatology · doi:10.1016/s0168-8278(08)60127-0 · Cited by 3 · see citing works
Halilbasic, E., Claudel, T., Bachhofner, N., Kapusta, C., & Trauner, M. A. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60358-4 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The UDP-Glycosyltransferase (UGT) Superfamily: New Members, New Functions, and Novel Paradigms
Meech, R., Hu, D. G., McKinnon, R. A., Mubarokah, S. N., Haines, A. Z., Nair, P. C., Rowland, A., & Mackenzie, P. I. (2019) · Physiological Reviews · doi:10.1152/physrev.00058.2017 · Cited by 363 · see citing works
Mechanisms of bile acid mediated inflammation in the liver
Li, M., Cai, S., & Boyer, J. L. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.001 · Cited by 268 · see citing works
Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease
Hegyi, P., Maléth, J., Walters, J. R., Hofmann, A. F., & Keely, S. J. (2018) · Physiological Reviews · doi:10.1152/physrev.00054.2017 · Cited by 269 · see citing works
Bile acid metabolism and signalling in liver disease
Fuchs, C. D., Simbrunner, B., Baumgartner, M., Campbell, C., Reiberger, T., & Trauner, M. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.032 · Cited by 246 · see citing works
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Jiao, T., Ma, Y., Guo, X., Ye, Y., & Xie, C. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00880-z · Cited by 122 · see citing works
“Therefore, the hepatic elimination of NorUDCA is lower than UDCA, enabling the enrichment of NorUDCA in liver [174, 175].”
BackgroundDana, J., Debray, D., Bèaufrere, A., Hillaire, S., Fabrè, M., Reinhold, C., Baumert, T. F., Berteloot, L., & Vilgrain, V. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.042 · Cited by 109 · see citing works
Cabrera, D., Arab, J. P., & Arrese, M. A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_241 · Cited by 100 · see citing works
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 84 · see citing works
Radun, R., & Trauner, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1731707 · Cited by 81 · see citing works
Recent Advances in the Management of Primary Sclerosing Cholangitis
Assis, D. N., & Bowlus, C. L. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.004 · Cited by 55 · see citing works
Alam, S., & Lal, B. B. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i1.98 · Cited by 47 · see citing works
Bile Acids in Cholestasis and its Treatment
Arab, J. P., Cabrera, D., & Arrese, M. A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5497 · Cited by 47 · see citing works
Nonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 43 · see citing works
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
Lazarević, S., Đanić, M., Goločorbin-Kon, S., Al‐Salami, H., & Mikov, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104333 · Cited by 40 · see citing works
Sohail, M. I., Çakıl, Y. D., Szöllősi, D., Stockner, T., & Chiba, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020784 · Cited by 39 · see citing works
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Urbani, G., Morretta, E., Monti, M. C., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159218 · Cited by 32 · see citing works
Trauner, M. A., Karpen, S. J., & Dawson, P. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001438 · Cited by 26 · see citing works
“…of CFTR-independent HCO 3 – secretion via TMEM16A), PBC, non-anastomotic strictures after liver transplantation (also linked to impaired expression/function of MDR3/ABCB4) and MASLD (microcholestasis) [249] with already ongoing phase II trials in PBC (EudraCT2021-001431-56) and MASH (NCT05083390).”
InfluentialPrimary Biliary Cholangitis and Primary Sclerosing Cholangitis Therapy Landscape
Bhushan, S. R., Sohal, A., & Kowdley, K. V. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003174 · Cited by 29 · see citing works
ABCB4/MDR3 in health and disease – at the crossroads of biochemistry and medicine
Prescher, M., Kroll, T., & Schmitt, L. (2019) · Biological Chemistry · doi:10.1515/hsz-2018-0441 · Cited by 25 · see citing works
Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases
Li, Y., & Lu, L. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00025 · Cited by 25 · see citing works
“mansoni infection-induced liver fibrosis and even bile duct ligation-induced cholemic nephropathy.(34,35) It has also been reported that norUDCA significantly improved liver biochemistry, in a dose-dependent manner, in PSC patients during a 12-week treatment and showed less toxicity compared to UDCA.”
ResultRole of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value
Li, Z.-J., Gou, H.-Z., Zhang, Y., Song, X., & Zhang, L. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i44.6213 · Cited by 23 · see citing works
Bile Acids—A Peek Into Their History and Signaling
Nguyen, J. T., Shaw, R. P. H., & Anakk, S. (2022) · Endocrinology · doi:10.1210/endocr/bqac155 · Cited by 22 · see citing works
Fiorucci, S., Urbani, G., Giorgio, C. D., Biagioli, M., & Distrutti, E. (2024) · Cells · doi:10.3390/cells13191650 · Cited by 22 · see citing works
Diagnosis, follow-up and treatment of cystic fibrosis-related liver disease
van de Peppel, I. P., Bertolini, A., Jonker, J. W., Bodewes, F. A. J. A., & Verkade, H. J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000428 · Cited by 20 · see citing works
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
Ronca, V., Carbone, M., Bernuzzi, F., Malinverno, F., Mousa, H. S., Gershwin, M. E., & Invernizzi, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1391093 · Cited by 18 · see citing works
Giorgio, C. D., Urbani, G., Marchianò, S., Biagioli, M., Bordoni, M., Bellini, R., Massa, C., Lachi, G., Cari, L., Morretta, E., et al. (2025) · Liver International · doi:10.1111/liv.16235 · Cited by 17 · see citing works
Hof, W. F. J., de Boer, J. F., & Verkade, H. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2336986 · Cited by 16 · see citing works
“Moreover, compounds such as systemic IBAT inhibitors [150], protein potentiators [130], chaperones [161,162,163], FXR agonists [151], FGF19 mimetics [164] and norucholic acid [165] have shown promising results in vitro or as experimental treatments.”
Li, X., Hu, L., Chu, H., Chen, L., Yan, J., Wang, W., Yang, X., Zhu, Q., Du, F., Song, Y., et al. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00398 · Cited by 15 · see citing works
Yuan, W.-H., Zhang, Z., Pan, Q., Mao, B., & Yuan, T. (2024) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v16.i1.103 · Cited by 10 · see citing works
Precision medicine in primary sclerosing cholangitis
Maurice, J. B., & Thorburn, D. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12788 · Cited by 10 · see citing works
“enrichment of bicarbonate in bile, mitigating the toxic effects seen at lower pH values.(52) This was tested in a phase II trial of 161 patients with PSC, ALP ≥1.”
BackgroundEmerging Therapeutic Strategies in the Fight Against Primary Biliary Cholangitis
Medford, A., Childs, J. R., Little, A., Chakraborty, S., Baiocchi, L., Alpini, G. D., & Glaser, S. S. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00398 · Cited by 8 · see citing works
Panuganti, V. K., Alluri, C. V., Mohammad, J., Dundigalla, M. R., Madala, P. K., KSSVV, S., & shaik, A. H. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113658 · Cited by 6 · see citing works
Yang, R., Du, C., Cao, T., Wang, G., Jiang, X. M., Jun, G., Lin, T., Sun, C., Ding, R., Tian, W., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15010107 · Cited by 6 · see citing works
Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
Kasztelan‐Szczerbińska, B., Rycyk, A., Szczerbińska, A., & Cichoż‐Lach, H. (2023) · Nutrients · doi:10.3390/nu15030760 · Cited by 6 · see citing works
“, norursodeoxycholic acid (norUDCA), has been introduced recently as a novel therapeutic approach in cholestatic and metabolic liver diseases with a specific focus on PSC treatment [181].”
BackgroundSahu, R., Mishra, R., & Majee, C. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1797485 · Cited by 5 · see citing works
“counteracted by bicarbonate-rich bile induced by Nor-UDCA administration [102].”
BackgroundMonomeric bile acids modulate the ATPase activity of detergent-solubilized ABCB4/MDR3
Kroll, T., Smits, S. H. J., & Schmitt, L. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100087 · Cited by 5 · see citing works
“Nor-UDCA is seen as a novel approach in cholestatic and metabolic liver diseases (29, 30).”
BackgroundSrikanth, P., Shaik, K. M., Patibandla, V., Kumar, D., & Nandi, S. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101425 · Cited by 3 · see citing works
Current and future opportunities for the management of primary biliary cholangitis
Naffouj, S., & Wang, J. R. (2023) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2023.1241901 · Cited by 3 · see citing works
“It is also distinguished by its intrahepatic enrichment, leading to a possible role in non-cholestatic metabolic and in fl ammatory liver disease (41).”
Bile acid therapy for primary biliary cholangitis: Pathogenetic validation
Reshetnyak, V. I., & Maev, I. V. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i1.101771 · Cited by 3 · see citing works
Jalan‐Sakrikar, N., Anwar, A. A., Ali, A., Nasser‐Ghodsi, N., Felzen, A., Huebert, R. C., LaRusso, N. F., & O’Hara, S. P. (2026) · Physiological Reviews · doi:10.1152/physrev.00022.2025 · Cited by 2 · see citing works
Pathophysiologic Basis for Alternative Therapies for Cholestasis
Fuchs, C. D., Halilbasic, E., & Trauner, M. A. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch30 · Cited by 2 · see citing works
An update on cystic fibrosis Hepato-biliary involvement
Freeman, A. J., & Bodewes, F. A. J. A. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.03.022 · Cited by 1 · see citing works
Fuchs, C. D., Petrenko, O., Mlitz, V., Dixon, E. D., Scharnagl, H., Ghallab, A., Reiberger, T., Garfinkel, B. P., & Trauner, M. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00071-1 · Cited by 1 · see citing works
“As such, its side chain shortened derivative norucholic acid (NCA, formerly norUDCA), exerting sub-stantialdifferencesinphysicochemicaland physiobiological properties compared to UDCA, was developed for treatment of PSC and other cholestatic liver diseases 10,11 .”
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis
Pham, H. N., Pham, L., & Sato, K. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2362263 · Cited by 1 · see citing works
“Norursodeoxycholic acid (norUDCA), a derivative of UDCA with a shortened side chain, is proposed to have potential therapeutic effects on hepatic inflammation and fibrogenesis in PSC [30].”
BackgroundPanuganti, V. K., Alluri, C. V., Dundigalla, M. R., Mohammad, J., Madala, P. K., & V., S. K. S. S. V. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/6613969 · Cited by 1 · see citing works
“Tis enrichment enables norUDCA to directly exert therapeutic efects on both parenchymal and non-parenchymal liver cells, thereby alleviating cholestasis, steatosis, hepatic infammation, and fbrosis, reducing hepatocellular proliferation, and promoting autophagy [3].”
Laurent, N. F., Lefevre, M. A., Dubois, S., & Robert, A. (2025) · Pharmaceutical Sciences and Drug Design · doi:10.51847/1fsubm6pym · Cited by 1 · see citing works
Zhu, C., Boucheron, N., Rîca, R., Stolz, V., Halilbasic, E., Claudel, T., Al-Rubaye, O., Lercher, A., Baumgartner, M., Sandner, L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.10.479975 · Cited by 1 · see citing works
[Advances in medical therapy of hypertension].
Orbegozo, J. M. R. (1953) · PubMed
Patent Highlights June–July 2021
Mucke, H. A. (2021) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2021-0022
Yin, D., Wu, W., Wang, X., He, J., Zhu, Y., & Li, J. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1764479
“A well-documented instance is nor-ursodeoxycholic acid, which improves MASLD pathological progression through its antifibrotic, anti-inflammatory, and antilipotoxic effects (Halilbasic et al., 2017).”
Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review
Malakar, S., Sood, N., Giri, S., & Samanta, A. (2026) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.120122
Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review
Cao, G., Zhao, H., Lin, G., Chen, J., Gao, C., Méndez‐Sánchez, N., Gao, F., & Qi, X. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03696-z
Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Sandhu, S., & Goel, A. (2026) · Seminars in Liver Disease · doi:10.1055/a-2952-2261
“C-C motif chemokine ligand 24 (CCL24) is a soluble pro-fi brotic, pro-in fl ammatory chemokine implicated in hepatic in fl ammation and fi brosis.”
Bile acid-based therapeutics: recent advances in bile acid conjugates and derivatives
Seo, M., Lee, J.-H., Yang, S.-B., Ma, G., Lee, H., Han, J., Ryu, Y., & Park, J. (2026) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-026-00830-5
- Authors
- Halilbasic, E., Steinacher, D., & Trauner, M.
- Affiliations
- Medical University of Vienna (AT)
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 35
- Issue
- 3
- Pages
- 288-292
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2594266717
- Cited by
- 55
- References
- 23
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 8 · 2023: 4 · 2022: 9 · 2021: 6 · 2020: 2 · 2019: 5 · 2018: 2 · 2017: 4
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- cholestasis, primary sclerosing cholangitis, bile acids, hepatic steatosis, liver fibrosis, hepatocyte proliferation, autophagy, metabolic liver disease, bile duct disorders
- MeSH terms
- Animals, Cholestasis, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Liver Diseases, Metabolic Diseases, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
